Baijin Life Science Holdings Ltd
01466
Company Profile
Business description
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewellery business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewellery business segment. Geographically, the company operates in The Group mainly operates in The United States of America(USA), Hong Kong, the PRC, and Others. It generates maximum revenue from Hong Kong.
Contact
66 Gloucester Road
Office B, 9th Floor, Pico Tower
Wanchai
Hong Kong
HKGT: +852 36112188
Sector
Consumer Cyclical
Stock type
Cyclical
Industry
Luxury Goods
Fiscal Year End
31 March 2027
Employees
84
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,859.20 | 4.50 | 0.05% |
| CAC 40 | 7,802.90 | 94.29 | -1.19% |
| DAX 40 | 25,224.06 | 7.14 | -0.03% |
| Dow JONES (US) | 50,907.68 | 269.28 | -0.53% |
| FTSE 100 | 10,461.22 | 0.73 | -0.01% |
| HKSE | 24,040.34 | 68.05 | 0.28% |
| NASDAQ | 27,369.35 | 178.49 | 0.66% |
| Nikkei 225 | 69,946.86 | 1,637.40 | 2.40% |
| NZX 50 Index | 13,699.02 | 18.53 | 0.14% |
| S&P 500 | 7,736.45 | 13.73 | 0.18% |
| S&P/ASX 200 | 8,686.40 | 4.30 | 0.05% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |